Abstract Purpose of Review Stroke is a leading cause of death and disability worldwide. The
annual incidence of new or recurrent stroke is approximately 795,000 cases per year in the …

Background Acute telogen effluvium is a non-scaring hair loss, usually occurs 3 months after
the stressful event that causes hair shedding, and lasts up to 6 months. It can be associated …

Telogen effluvium post-COVID-19 is a condition characterized by the diffuse and reversible
loss of scalp hair in the period following infection with SARS-CoV-2, and it is currently the …

Telogen effluvium (TE) is one of the most common form of hair loss in women. Many triggers
have been identified, as stress, drugs, trauma, endocrine disease, nutritional deficiencies …

Background The cutaneous manifestations of COVID-19 may be useful disease markers and
prognostic indicators. Recently, postinfectious telogen effluvium and trichodynia have also …

COVID‐19 is a febrile, infectious illness that has previously been associated with telogen
effluvium (TE). However, to date, no study has been conducted to determine the incidence of …

Post-SARS-CoV-2 telogen effluvium has been described in case reports of COVID-19
patients. We evaluated the prevalence of post-SARS-CoV-2 telogen effluvium in patients …

Background: The prevalence of lung cancer is 14% among the newly diagnosed cancer
cases worldwide. Currently, the number of drugs that are in clinical practice is having a high …

With a practice dedicated to hair restoration and hair loss management, the authors have
seen a large number of patients presenting with increased hair fall in the last 18 months …

The prevention and treatment of venous thromboembolism (VTE) poses distinct gender‐
specific challenges. Women of childbearing age are at an increased risk of VTE secondary …